Park National Corp OH cut its position in shares of Zoetis Inc (NYSE:ZTS) by 4.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 128,877 shares of the company’s stock after selling 5,781 shares during the period. Zoetis comprises about 1.1% of Park National Corp OH’s investment portfolio, making the stock its 25th largest position. Park National Corp OH’s holdings in Zoetis were worth $21,312,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Hoover Financial Advisors Inc. bought a new stake in shares of Zoetis during the second quarter valued at approximately $27,000. Lipe & Dalton bought a new stake in shares of Zoetis during the second quarter valued at approximately $30,000. Demars Financial Group LLC bought a new stake in shares of Zoetis during the second quarter valued at approximately $30,000. Campbell Wealth Management bought a new stake in shares of Zoetis during the second quarter valued at approximately $34,000. Finally, Engrave Wealth Partners LLC increased its position in shares of Zoetis by 32.5% during the second quarter. Engrave Wealth Partners LLC now owns 302 shares of the company’s stock valued at $41,000 after purchasing an additional 74 shares during the period. Institutional investors and hedge funds own 92.50% of the company’s stock.
In other Zoetis news, EVP Catherine A. Knupp sold 13,000 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $158.86, for a total value of $2,065,180.00. Following the transaction, the executive vice president now owns 53,368 shares of the company’s stock, valued at $8,478,040.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $152.19, for a total value of $179,432.01. Following the completion of the transaction, the executive vice president now directly owns 17,514 shares in the company, valued at approximately $2,665,455.66. The disclosure for this sale can be found here. Insiders have sold 34,830 shares of company stock worth $5,524,068 in the last ninety days. 0.17% of the stock is currently owned by insiders.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.25. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same quarter in the prior year, the firm posted $0.90 earnings per share. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, equities research analysts expect that Zoetis Inc will post 3.62 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on ZTS shares. Stifel Nicolaus boosted their price objective on Zoetis from $155.00 to $170.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Citigroup upped their price target on Zoetis from $146.00 to $160.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Argus reiterated a “buy” rating on shares of Zoetis in a research report on Wednesday, June 3rd. G.Research cut Zoetis from a “buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Morgan Stanley upped their price target on Zoetis from $125.00 to $167.00 and gave the company an “equal weight” rating in a research report on Thursday, August 20th. Ten investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and an average target price of $155.14.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: What is the S&P/ASX 200 Index?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.